Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences by Year
Alpine Immune Sciences — Stock-based compensation expense ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences: $10.6M in FY2023, up 10.2% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Stock-based compensation expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 10.6 | +10.2% | SEC Filing ↗ |
| FY2022 | Dec 31, 2022 | 9.65 | +54.6% | SEC Filing ↗ |
| FY2021 | Dec 31, 2021 | 6.24 | +50.7% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 4.14 | +36.2% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 3.04 | +31.6% | SEC Filing ↗ |
| FY2018 | Dec 31, 2018 | 2.31 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences ($M), annual FY2018–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-sbc-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.